8-K current report · filed Nov 4, 2026

Medline Inc (MDLN) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1MDLN overview

Short answer

Medline Inc (MDLN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Medline’s Q3 and first-nine-month results released for period ended September 26, 2026.

Medline Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Medline’s Q3 and first-nine-month results released for period ended September 26, 2026
  • Investors should review Exhibit 99.1 for revenue, earnings, margins and outlook details

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net sales $7.9B, up 10.4%, while net income fell 1.2% to $318M, signaling growth with margin pressure
  • Q3 Adjusted EBITDA $960M, up 11.8%, but gross margin declined to 24.5% from 26.4%
  • Nine-month net income down 28.8% to $696M, burdened by $316M in Tracy fire losses and higher operating costs
  • Organic Sales guidance raised to 10.0%-10.5%, while Adjusted EBITDA guidance remains $3.3B-$3.4B
  • $1B share repurchase authorized alongside $750M repayment of the 2033 Refinancing Term Loan Facility

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Medline Inc 8-K filings

Get the next MDLN 8-K as it lands

Follow MDLN for push alerts, or ask the research agent what this filing means.